283 related articles for article (PubMed ID: 23571771)
21. [Analysis of Spontaneously Reported Adverse Events].
Nakamura M
Yakugaku Zasshi; 2016; 136(4):549-56. PubMed ID: 27040337
[TBL] [Abstract][Full Text] [Related]
22. An experimental investigation of masking in the US FDA adverse event reporting system database.
Wang HW; Hochberg AM; Pearson RK; Hauben M
Drug Saf; 2010 Dec; 33(12):1117-33. PubMed ID: 21077702
[TBL] [Abstract][Full Text] [Related]
23. Evidence of Misclassification of Drug-Event Associations Classified as Gold Standard 'Negative Controls' by the Observational Medical Outcomes Partnership (OMOP).
Hauben M; Aronson JK; Ferner RE
Drug Saf; 2016 May; 39(5):421-32. PubMed ID: 26879560
[TBL] [Abstract][Full Text] [Related]
24. An OMOP-CDM based pharmacovigilance data-processing pipeline (PDP) providing active surveillance for ADR signal detection from real-world data sources.
Shin H; Lee S
BMC Med Inform Decis Mak; 2021 May; 21(1):159. PubMed ID: 34001114
[TBL] [Abstract][Full Text] [Related]
25. Suboptimal reporting of adverse medical events to the FDA Adverse Events Reporting System by nurse practitioners and physician assistants.
Ehrenpreis ED; Sifuentes H; Ehrenpreis JE; Smith ZL; Marshall ML
Expert Opin Drug Saf; 2012 Mar; 11(2):177-83. PubMed ID: 22316142
[TBL] [Abstract][Full Text] [Related]
26. Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations.
Kadoyama K; Miki I; Tamura T; Brown JB; Sakaeda T; Okuno Y
Int J Med Sci; 2012; 9(1):33-9. PubMed ID: 22211087
[TBL] [Abstract][Full Text] [Related]
27. On the evidence consistency of pharmacovigilance outcomes between Food and Drug Administration Adverse Event Reporting System and electronic medical record data for acute mania patients.
Duan R; Zhang X; Du J; Huang J; Tao C; Chen Y
Health Informatics J; 2020 Jun; 26(2):753-764. PubMed ID: 30887861
[TBL] [Abstract][Full Text] [Related]
28. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system.
Sakaeda T; Kadoyama K; Okuno Y
PLoS One; 2011; 6(12):e28124. PubMed ID: 22205938
[TBL] [Abstract][Full Text] [Related]
29. Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions.
Li Y; Jimeno Yepes A; Xiao C
Drug Saf; 2020 Sep; 43(9):893-903. PubMed ID: 32385840
[TBL] [Abstract][Full Text] [Related]
30. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
[TBL] [Abstract][Full Text] [Related]
31. Mechanism-based Pharmacovigilance over the Life Sciences Linked Open Data Cloud.
Kamdar MR; Musen MA
AMIA Annu Symp Proc; 2017; 2017():1014-1023. PubMed ID: 29854169
[TBL] [Abstract][Full Text] [Related]
32. Standard-based comprehensive detection of adverse drug reaction signals from nursing statements and laboratory results in electronic health records.
Lee S; Choi J; Kim HS; Kim GJ; Lee KH; Park CH; Han J; Yoon D; Park MY; Park RW; Kang HR; Kim JH
J Am Med Inform Assoc; 2017 Jul; 24(4):697-708. PubMed ID: 28087585
[TBL] [Abstract][Full Text] [Related]
33. Prospective data mining of six products in the US FDA Adverse Event Reporting System: disposition of events identified and impact on product safety profiles.
Bailey S; Singh A; Azadian R; Huber P; Blum M
Drug Saf; 2010 Feb; 33(2):139-46. PubMed ID: 20082540
[TBL] [Abstract][Full Text] [Related]
34. Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system.
Kadoyama K; Sakaeda T; Tamon A; Okuno Y
Biol Pharm Bull; 2012; 35(6):967-70. PubMed ID: 22687540
[TBL] [Abstract][Full Text] [Related]
35. Logistic regression in signal detection: another piece added to the puzzle.
Caster O; Norén GN; Madigan D; Bate A
Clin Pharmacol Ther; 2013 Sep; 94(3):312. PubMed ID: 23695184
[No Abstract] [Full Text] [Related]
36. Influence of the MedDRA hierarchy on pharmacovigilance data mining results.
Pearson RK; Hauben M; Goldsmith DI; Gould AL; Madigan D; O'Hara DJ; Reisinger SJ; Hochberg AM
Int J Med Inform; 2009 Dec; 78(12):e97-e103. PubMed ID: 19230751
[TBL] [Abstract][Full Text] [Related]
37. Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS.
Sakaeda T; Kadoyama K; Yabuuchi H; Niijima S; Seki K; Shiraishi Y; Okuno Y
Int J Med Sci; 2011; 8(4):332-8. PubMed ID: 21611115
[TBL] [Abstract][Full Text] [Related]
38. Response to "Logistic regression in signal detection: another piece added to the puzzle".
Harpaz R; DuMouchel W; LePendu P; Bauer-Mehren A; Ryan P; Shah NH
Clin Pharmacol Ther; 2013 Sep; 94(3):313. PubMed ID: 23756371
[No Abstract] [Full Text] [Related]
39. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.
Szarfman A; Machado SG; O'Neill RT
Drug Saf; 2002; 25(6):381-92. PubMed ID: 12071774
[TBL] [Abstract][Full Text] [Related]
40. Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System.
Stobaugh DJ; Deepak P; Ehrenpreis ED
J Am Acad Dermatol; 2013 Sep; 69(3):393-8. PubMed ID: 23683730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
